Embracing Personalization in Biopharma Patient Support Programs
Fierce Pharma
APRIL 18, 2023
Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48
Rising Investment in Patient Support Drives a Greater Biopharma Focus on Measurement
Fierce Pharma
FEBRUARY 27, 2024
Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support. A seismic shift has occurred in the healthcare landscape.
Biopharma 
181
181 
The Direct-to-Patient Platform: Transforming the Patient Journey for Better Outcomes
Fierce Pharma
OCTOBER 3, 2024
Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)
Patients 130
130 
Here’s how biopharma can better support patients while they’re searching for care
Fierce Pharma
SEPTEMBER 27, 2024
Patients with rare or complex diseases often struggle to find specialists who meet their specific condition and individual needs. Patients with rare or complex diseases struggle to find specialists who fit their unique needs, delaying crucial care. Digital tools can help.
Biopharma 130
130 
Biopharma’s AI revolution is about more than algorithms
Fierce Pharma
SEPTEMBER 19, 2023
With the right infrastructure, intelligent tools stand to not only process data but also improve clinical decision-making—helping find more patients for biopharma companies, and faster, too. Especially with the proliferation of AI in other industries and chatGPT.
Biopharma 222
222 
Fierce Pharma Asia—Enhertu's encore; Akeso's showstopper; GenScript and Legend's US scrutiny
Fierce Pharma
JUNE 6, 2024
AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. lawmakers.
Biopharma 186
186 
Pfizer acquires biopharma firm Biohaven for $11.6bn
Pharmaceutical Technology
OCTOBER 4, 2022
Treatments to enhance the lives of debilitating neurological and neuropsychiatric disease patients are part of Biohaven’s portfolio. Combined with Pfizer’s global reach, this acquisition increases our potential to bring new treatment options to patients with migraine – a disease which affects over one billion people worldwide.”.
Biopharma 106
106 
FTC order could ease biopharma competition
European Pharmaceutical Review
SEPTEMBER 4, 2023
The biopharma company will be required to seek prior approval before acquiring related products. BIO stated that the settlement will enable the FTC to protect competition, while facilitating rare disease patients to promptly benefit from the deal’s pro-competitive advantages. Divest to invest: the new normal in biopharma?
Competition 98
98 
Roche to acquire biopharma firm Good Therapeutics for $250m
Pharmaceutical Technology
SEPTEMBER 8, 2022
We have focused on PD-1-IL-2 as a biology that has great potential for benefiting patients.”. The post Roche to acquire biopharma firm Good Therapeutics for $250m appeared first on Pharmaceutical Technology.
Biopharma 111
111 
Lilly completes biopharma acquisitions
European Pharmaceutical Review
AUGUST 14, 2023
The goal of such therapies is to free patients from constant disease management by sensing blood glucose levels, restoring insulin production and releasing it over the long term. “By The post Lilly completes biopharma acquisitions appeared first on European Pharmaceutical Review. Both companies have been working together since 2018.
Biopharma 98
98 
How Tech Changes to Clinical Trials Help Both Patients and Biopharma Firms
MedCity News
OCTOBER 27, 2023
Technology is transforming how clinical trials are run. A panel during MedCity News’ INVEST Digital Health conference discussed the tech trends shaping the design and execution of drug studies.
Biopharma 120
120 
EU pharmaceutical legislation revisions: what are the implications for biopharma?
European Pharmaceutical Review
DECEMBER 20, 2023
1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. The second is an adjustment of unmet need categorisation required for RDP extension; unmet need definition now encompasses ‘meaningful’ impact patient outcomes (notably including quality of life).
Biopharma 98
98 
Divest to invest: the new normal in biopharma?
European Pharmaceutical Review
AUGUST 24, 2023
This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. The post Divest to invest: the new normal in biopharma?
Biopharma 98
98 
Elevating patient care from the home
MedCity News
JULY 20, 2022
By adding adherence and connectivity capabilities to home-based solutions, clinicians can maintain open lines of communication with patients, helping patients better care for themselves from the comfort of their homes.
Patients 134
134 
Pharma Pulse 6/17/24: Pet Care Industry Eyes GLP-1s, Improving Quality of Care for Cancer Patients & more
Pharmaceutical Commerce
JUNE 17, 2024
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
Distribution 103
103 
Pharma Pulse 8/8/24: Addressing Maternal Health Disparities and Driving Change, Abacavir Increases Cardiovascular Risk in Patients With HIV & more
Pharmaceutical Commerce
AUGUST 8, 2024
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
Distribution 104
104 
Fierce Pharma Asia—Takeda restructures; Lilly, Innovent tout GLP-1 win; BIO warns of decoupling damage
Fierce Pharma
MAY 9, 2024
A BIO survey of biopharma companies indicated that a sudden break-off from Chinese CDMOs could harm millions of patients. Innovent Biologics' GLP-1R/GCGR dual agonist, licensed from Eli Lilly, has notched a second positive phase 3 rea | Takeda launched a restructuring to achieve “organizational simplicity.” And more.
Biopharma 130
130 
Patient Voice and Patient Choice: Essentials for Successful DCTs
MedCity News
DECEMBER 19, 2022
Historically, clinical trials have not prioritized the experiences of patients, who are required to frequently return on-site and engage with unfamiliar medical technology. They are often left in the dark regarding the data and health outcomes being collected through their participation.
Patients 105
105 
FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery
MedCity News
APRIL 23, 2024
ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The post FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery appeared first on MedCity News. The novel immunotherapy works by sparking activity from three types of immune cells.
FDA 127
127 
An Attack on Patients’ Right to Informed Consent
MedCity News
MARCH 6, 2024
This case, about the claim that Merck failed to warn patients about the risk of typical femoral fracture, reaches past this suit to potentially change pharmaceutical companies’ relationship with the FDA.
Patients 118
118 
The PharmaVoice 100: Rare disease warriors
PharmaVoice
OCTOBER 16, 2023
Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.
Biopharma 110
110 
With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs
MedCity News
SEPTEMBER 4, 2024
Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players.
Patients 128
128 
Telehealth Can Broaden Reach of Palliative Care for Lung Cancer Patients, Per MGH Study
MedCity News
JUNE 16, 2024
Investigators say these results indicate telehealth can make palliative care accessible to more cancer patients. The post Telehealth Can Broaden Reach of Palliative Care for Lung Cancer Patients, Per MGH Study appeared first on MedCity News.
Patients 126
126 
How Patient Monitoring Is Poised to Revolutionize Healthcare
MedCity News
FEBRUARY 26, 2023
Wearable patient devices can provide healthcare organizations with more varied data, expand options for clinical trials, and make patients more active participants in their own care.
Healthcare 120
120 
New mass spectrometry Chapter could “revolutionise” biopharma quality assurance
European Pharmaceutical Review
DECEMBER 2, 2024
The recognition of mass spectrometry as a complementary method opens the door for us to support biopharmaceutical developers in getting their drugs approved for clinical trials and patient treatment,” Mørtz continued.
Biopharma 52
52 
$1.7b acquisition to develop rare haematology therapy
European Pharmaceutical Review
MAY 12, 2023
Swedish Orphan Biovitrum AB (Sobi ® ) has agreed to acquire CTI BioPharma for $1.7 There is a large unmet medical need within myelofibrosis, in particular for patients suffering from thrombocytopenia who are inadequately treated by existing medicines.
Allying With Patients to Make Every Cure Possible
MedCity News
MAY 22, 2024
To win the battle against rare diseases, drug developers must work hand-in-hand with patients. The post Allying With Patients to Make Every Cure Possible appeared first on MedCity News.
Patients 95
95 
FDA Approves First Drug for Treating Agitation in Alzheimer’s Patients
MedCity News
MAY 11, 2023
Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
FDA 123
123 
What the Radiopharmaceutical Pipeline Means for Patient Care
MedCity News
OCTOBER 16, 2023
With increased access to cutting-edge imaging, improved treatment options, greater personalization of treatment, reduced radiation exposure, and potential for future advances, patients can expect to receive more advanced medical care tailored to their specific needs through radiopharmaceuticals.
Patients 114
114 
The Key To Faster, More Efficient Clinical Trials? Patient Centricity
MedCity News
DECEMBER 8, 2022
Added complexity to daily life is likely why patient dropout rates remain high, with 19% leaving studies before completion. Truly patient-centric trials will allow for broader participation, allowing patients to decide how and when they want to engage in a study.
Patients 104
104 
Generative AI’s potential to speed delivery of improved patient outcomes
Clarivate
JUNE 29, 2023
We’re mindful of some challenges that life science and healthcare organizations must work through before this technology is mature enough for use in critical business decisions that may impact patient health. Our customers entrust our products and services to help them improve patient health, and we will not jeopardize that mission.
Patients 98
98 
Putting patients at the center of RWD collection processes [Sponsored]
MedCity News
AUGUST 30, 2022
the European Union and other countries amid ongoing efforts to encourage patients who want to share their data. In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S.,
Patients 109
109 
A sad day for us all as the FDA continues to lose credibility
World of DTC Marketing
JUNE 8, 2021
The Financial Times said , “Michael Carome, director of the health research group at Public Citizen, said, “these costs to patients, to their families, are just not justified based upon what we know about this drug”. There are no efficacy data to clearly demonstrate this drug helps patients. Nowhere to be seen.
FDA 207
207 
Novartis collaboration to innovate subcutaneous drug delivery
European Pharmaceutical Review
AUGUST 28, 2024
This platform enables high concentrations of biologics to be delivered in a single dose, improving the convenience of administration and patient and treatment compliance, according to Lindy Biosciences. Lindy Biosciences will receive an upfront payment of $20 million as part of the transaction. percent).
Biopharma 110
110 
Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative
MedCity News
SEPTEMBER 5, 2024
Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. The post Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative appeared first on MedCity News.
Patients 104
104 
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
MedCity News
NOVEMBER 22, 2024
A patient death in a clinical trial usually prompts the FDA to impose a clinical hold. The post Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose appeared first on MedCity News.
FDA 100
100 
Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients
MedCity News
JULY 18, 2024
Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). The post Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients appeared first on MedCity News. Phathom licensed its flagship product from Takeda Pharmaceutical.
Pharma 101
101 
Streamlining Clinical Research Through Patient Centricity: Addressing Key Challenges Impeding Administrative Operations
MedCity News
NOVEMBER 1, 2023
Investing in comprehensive patient concierge services keeps trial administrators on track by removing the burden of logistical support and improving the overall participant experience, making dropouts and trial delays much less likely.
Patients 114
114 
Patient Death Prompts FDA Hold on Tests of Drug in Atopic Dermatitis & Asthma
MedCity News
FEBRUARY 20, 2024
The FDA clinical hold follows a patient death from liver failure that may be associated with zelnecirnon, an experimental Rapt Therapeutics drug. The biotech notes that no other patient has experienced liver problems and this safety signal has not been seen in any other tests of the molecule.
FDA 101
101 
The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients
MedCity News
JUNE 21, 2024
The post The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients appeared first on MedCity News. Underrepresentation of racial and ethnic groups and other historically disenfranchised populations in clinical trials continues to be a major challenge. Medical Affairs can help identify solutions.
Medical 106
106 
Umoja and IASO partner to develop therapies for haematological malignancies
Pharmaceutical Technology
NOVEMBER 22, 2022
Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. In the initial stage, the partnership will focus on acute myeloid leukaemia (AML) to boost accessibility to patients.
Biopharma 110
110 
Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs
MedCity News
APRIL 8, 2024
The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products. The post Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs appeared first on MedCity News.
FDA 106
106 
The patient privacy factor in clinical trials
MedCity News
SEPTEMBER 7, 2022
In the first quarter of 2022, my personal life converged with my work life concerning […].
Patients 123
123 
Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence
MedCity News
NOVEMBER 10, 2024
The post Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence appeared first on MedCity News.
Patients 108
108 
Let's personalize your content